SAN DIEGO --(BUSINESS WIRE)--Sep. 21, 2023-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal
SAN DIEGO --(BUSINESS WIRE)--Mar. 24, 2023-- Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces enrollment of the first patient in the FORESEE clinical trial with the Company’s proprietary cerebrospinal fluid assay CNSide (NCT05414123).
University of Colorado-affiliated scientific leader to collaborate on assays for biopharmaceutical partners SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the diagnosis and treatment of cancer,
David F. Hale and Ivor Royston, M.D. Join Biocept Board The Board of Biocept, Inc. announced today that David F. Hale has joined the Board as Executive Chairman and Ivor Royston, M.D. as a Director. Mr. Hale and Dr. Royston first worked together at Hybritech, San Diego’s first biotech company, of
Clinically validated data demonstrate greater than 93% concordance in detecting EGFR mutation with tissue biopsy in 74 patients diagnosed with lung cancer
Target Selector™ platform shown to be potentially more sensitive than standard-of-care cytology in detecting mutations of brain metastases in cerebrospinal fluid SAN DIEGO , May 29, 2020 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed
Case series poster to be presented at the Society for Neuro-Oncology Annual Meeting SAN DIEGO --(BUSINESS WIRE)--Nov. 18, 2021-- Third paragraph, sixth sentence of release should read: CNSide detected CSF tumor cells in all eleven measurements taken, compared to six of eleven using cytology.
Study designed to address the significant medical need for rapidly and accurately diagnosing brain metastases in breast cancer patients to enable better treatment decisions
High concordance of the Company's Target-Selector™ platform enables real-time monitoring of key biomarkers in metastatic breast cancer, and provides an alternative when tissue biopsy is not an option
